Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.9652W HIGH $13.67
Volume
876.45 K
Value Traded
4.42 M
Short % Float
22.51%
+1.11%Week
-13.65%1 Month
-17.76%3 Month
-32.67%6 Month
-74.69%5 Year
-74.69%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
395.18 M
EPS (TTM)
-2.47
P/E Ratio
-
Ent. Value
220.64 M
Total Shares
61.84 M
Float Shares
38.95 M
Insiders
37.02%
Institutions
47.60%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
KYTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Kyverna Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kyverna Therapeutics, Inc.
173Total events
19Upcoming
38Tier-1 (high impact)
2023 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutKYV-101FiledClinical Data
Positive one-year topline data from KYSA-8 in SPS
stiff person syndromesource ↗
▲RMATKYV-101FiledDesignation
FDA grants RMAT designation for miv-cel in naSPMS
non-active secondary progressive multiple sclerosis (naSPMS)source ↗
▲Partnership / LicenseKYV-101FiledCorporate
Kyverna and ElevateBio enter into commercial manufacturing and supply agreement for miv-cel
▲Long Term DataKYV-101FiledClinical Data
12-month follow-up data on 26 patients with SPS
stiff person syndromesource ↗
▲Management ChangeCorporate
Appointment of Ritesh Srivastava as Chief Legal and Compliance Officer
●BLA SubmissionKYV-101FiledRegulatory Filing
Initiated rolling BLA submission for miv-cel in stiff person syndrome
stiff person syndromesource ↗
▲Trial CompletionKYV-101FiledTrial
Registrational trial in stiff person syndrome completed
stiff person syndromesource ↗
●Trial InitiationKYV-101FiledTrial
Ongoing registrational trial for generalized myasthenia gravis
generalized myasthenia gravissource ↗
▲Primary Endpoint MetKYV-101FiledClinical Data
All 7 patients achieved clinically meaningful improvement in MG-ADL and QMG co-primary endpoints at 24 weeks
generalized myasthenia gravissource ↗
▲Long Term DataKYV-101FiledClinical Data
Longer-term Phase 2 follow-up in gMG sustained up to 1.5 years
generalized myasthenia gravissource ↗
◆Oral PresentationPresentation
H.C. Wainwright 4th Annual Nasdaq BioConnect Conference Presentation
▲Trial CompletionKYV-101FiledTrial
Registrational trial in stiff person syndrome completed
stiff person syndromesource ↗
▲Pre BLA MeetingKYV-101FiledFDA Meeting
Positive pre-BLA meeting with FDA alignment on KYSA-8 single-arm trial
stiff person syndrome (SPS)source ↗
●BLA SubmissionKYV-101FiledRegulatory Filing
Initiation of rolling BLA submission for miv-cel in SPS
stiff person syndrome (SPS)source ↗
▲Enrollment UpdateKYV-101FiledTrial
Enrollment advances in Phase 3 trial in gMG
generalized myasthenia gravis (gMG)source ↗
▲Full ResultsKYV-101FiledClinical Data
Primary analysis results from KYSA-8 pivotal trial demonstrated robust, durable effect
stiff person syndrome (SPS)source ↗
▲Trial CompletionKYV-101FiledTrial
Registrational trial in stiff person syndrome completed
stiff person syndromesource ↗
▲Trial InitiationKYV-101FiledTrial
Ongoing registrational trial for generalized myasthenia gravis
generalized myasthenia gravissource ↗
◆Quarterly UpdateCorporate
Conference call to discuss primary analysis from KYSA-8 and longer-term follow-up from KYSA-6
●Enrollment UpdateKYV-101FiledTrial
Enrolling Phase 3 portion of KYSA-6 with 14 active clinical sites across three geographies
generalized myasthenia gravissource ↗
▲Oral PresentationKYV-101FiledPresentation
Primary analysis results from KYSA-8 registrational trial presented at AAN 2026
Stiff Person Syndrome (SPS)source ↗
●Poster PresentationKYV-101FiledPresentation
Design of Phase 3 of KYSA-6 in generalized myasthenia gravis
generalized myasthenia gravissource ↗
◆Oral PresentationKYV-101FiledPresentation
Primary analysis from KYSA-8 registrational trial of miv-cel in stiff person syndrome
stiff person syndromesource ↗
▲Primary Endpoint MetKYV-101FiledClinical Data
KYSA-8 met primary endpoint: statistically significant improvement in T25FW at Week 16 (p=0.0003)
stiff person syndromesource ↗
▲Full ResultsKYV-101FiledClinical Data
Full primary analysis results from KYSA-8 presented at AAN
stiff person syndromesource ↗
●Poster PresentationPresentation
Natural history study results presented at AAN
stiff person syndromesource ↗
◆Oral PresentationKYV-101FiledPresentation
Update on Phase 2 portion of KYSA-6 in generalized myasthenia gravis
generalized myasthenia gravissource ↗
●Poster PresentationKYV-101FiledPresentation
Real-world natural history study on Timed 25-Foot Walk in stiff person syndrome
stiff person syndromesource ↗
●Oral PresentationKYV-101FiledPresentation
Natural history study presented at 2026 AAN annual meeting
stiff person syndrome (SPS)source ↗
◆Oral PresentationPresentation
Leerink Partners 2026 Global Healthcare Conference Fireside Chat
▲Management ChangeCorporate
Appointment of Sravan K. Emany and Andrew Miller to Board of Directors
▲Trial CompletionKYV-101FiledTrial
Recently completed registrational trial in stiff person syndrome
stiff person syndromesource ↗
◆Trial InitiationKYV-101FiledTrial
Ongoing registrational trial for generalized myasthenia gravis
generalized myasthenia gravissource ↗
◆Oral PresentationPresentation
Kyverna CEO to present at J.P. Morgan 2026 Healthcare Conference
◆Management ChangeCorporate
Christi Shaw appointed Executive Chairperson; Ian Clark remains Director
●Timing GuidanceKYV-101FiledPresentation
BLA submission for miv-cel in SPS anticipated in 1H 2026
stiff person syndrome (SPS)source ↗
◆Timing GuidanceKYV-101FiledPresentation
Topline registrational data expected early 2026 (narrowed from 1H 2026)
stiff person syndromesource ↗
◆Topline ReadoutKYV-101FiledClinical Data
Topline data expected from registrational Phase 2 KYV-101 trial in stiff person syndrome
stiff person syndromesource ↗
◆Full ResultsKYV-101FiledClinical Data
Full registrational data from KYSA-8 to be reported in 1H 2026
stiff person syndrome (SPS)source ↗
Past FDA Catalysts and PDUFA Decisions
How KYTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-29 | miv-cel (mivocabtagene autoleucel, KYV-101) | Phase 2 data presentation | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C46 / 100
Pipeline Score
$94M
Pipeline Value
Overvalued
Valuation Signal
1
Drugs Scored
0.2x
rNPV / MCap
Top 25%
Micro Cap(rank 165 of 657)
Percentile Rank
Kyverna Therapeutics, Inc. carries a moderate pipeline score (46/100), with $453M risk-adjusted pipeline value, led by KYV-101 in Multiple Sclerosis (Phase 1), across $85B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| KYV-101 Monoclonal antibodyNCT06384976 | Multiple Sclerosis, Primary Progressive | Phase 2 | ACTIVE NOT_RECRUITING | 120 | Jan 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every KYTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| miv-cel RMAT | stiff person syndrome | Phase 2 | 2026-10-07 | sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS and no cases of IEC-HSRead More | Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| CLARK IAN TDirector | Grant/Award | 5,093 21,727 held | $0.00 | 05/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KYTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 1.5 % (-37.5 %) | 25.70 M | 2.88 M | -7.23% ( -225.00 K) |
KYTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KYTX ranks across every disease it competes in
Competitive Position is a premium feature
See how KYTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKYTX News
KYTXKyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
Kyverna Therapeutics announced positive results from the KYSA-8 trial for stiff person syndrome, showing sustained clinical benefits and a favorable safety profile. Additionally, updated data from a Phase 1 trial in progressive multiple sclerosis highlighted encouraging clinical activity. These findings will be presented at the upcoming MSToronto2026 meeting, reinforcing the potential of miv-cel as a groundbreaking therapy.
Read more →KYTXKyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
Kyverna Therapeutics has reported positive one-year data from its miv-cel trials for stiff person syndrome (SPS) and generalized myasthenia gravis (gMG). The data indicate sustained clinical benefits and a favorable safety profile, with a rolling BLA submission expected to be completed in Q4 2026. The results highlight miv-cel's potential as a transformative therapy in the treatment of these autoimmune diseases.
Read more →KYTXKyverna Therapeutics to Present at Upcoming Investor Conferences
Kyverna Therapeutics, a late-stage clinical immunology company, announced its participation in several upcoming investor conferences, including the Wells Fargo Healthcare Conference and the Morgan Stanley Global Healthcare Conference. The presentations will include fireside chats and investor meetings. Kyverna is focused on developing transformative therapies for neurologic autoimmune diseases, with its lead candidate showing promising results.
Read more →KYTXCompany Statement on Miv-cel's Favorable Safety Profile
Kyverna Pharmaceuticals reaffirms the favorable safety profile of miv-cel, its CD19 CAR T-cell therapy, amidst recent third-party reports. The therapy has been administered to over 100 patients, showing no high-grade adverse effects. Kyverna plans to complete its rolling BLA submission for stiff person syndrome by Q4 and aims to finish enrollment for its Phase 3 trial for generalized myasthenia gravis by mid-2027.
Read more →KYTXKyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
Kyverna Therapeutics has reported significant progress in its pipeline, particularly with miv-cel, which has received RMAT designation from the FDA for non-active secondary progressive multiple sclerosis. This designation is based on compelling clinical data, indicating a promising future for the therapy in neuroimmunology. Additionally, the company is on track to complete its rolling BLA submission for miv-cel in stiff person syndrome by the end of Q4.
Read more →KYTX▲ +6.9%on this news
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
Kyverna Therapeutics has entered a commercial manufacturing agreement with ElevateBio for miv-cel, an autologous CAR T-cell therapy. This partnership aims to support the U.S. commercial and global clinical supply of miv-cel, which is being developed for stiff person syndrome and generalized myasthenia gravis. The agreement strengthens Kyverna's readiness for potential product launches and is backed by ElevateBio's expertise in manufacturing.
Read more →KYTXKyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
Kyverna Therapeutics has appointed Ritesh Srivastava as Chief Legal and Compliance Officer to support its transition to a commercial-stage organization. Mr. Srivastava's extensive experience in legal and compliance will be crucial as Kyverna advances its CAR T-cell therapy, miv-cel, towards potential approval for stiff person syndrome. This appointment is part of Kyverna's strategic growth as it prepares for commercialization.
Read more →KYTXKyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
Read more →KYTX▼ -10%on this news
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
Read more →KYTX▼ -10%on this news
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer Veteran biopharma leader joins to help lead Kyverna's next phase of commercial growth
Kyverna Therapeutics has appointed Greg Martini as Chief Financial Officer, effective May 18, 2026, succeeding Dr. Marc Grasso. Martini brings substantial financial leadership experience, previously serving as CFO at Ironwood Pharmaceuticals. He will oversee Kyverna's financial strategy as it advances its lead product, miv-cel, toward potential approval and commercialization, particularly focusing on autoimmune diseases. This transition is seen as critical for the company's growth and long-term success in the biopharmaceutical field.
Read more →KYTX▲ +5.4%on this news· ran to -17% by day 3shared move
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
Kyverna Therapeutics has initiated a rolling BLA submission for its CAR T therapy, miv-cel, targeting stiff person syndrome (SPS), following a positive pre-BLA meeting with the FDA. The company reported strong financial results for Q1 2026 and is advancing its Phase 3 trial in generalized myasthenia gravis. The CEO emphasized the significance of this milestone for the company and the field of autoimmune therapies.
Read more →KYTXKyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
Kyverna Therapeutics has appointed Nadia Dac as Chief Commercial Officer, effective May 4, 2026. With extensive experience in the biopharmaceutical industry, she will lead the commercial strategy for miv-cel, a potential first treatment for stiff person syndrome. Dac's background includes significant roles at Omeros and AbbVie, enhancing Kyverna's leadership in neuroimmunology.
Read more →KYTX▲ +5.4%on this news
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
Kyverna Therapeutics presented longer-term Phase 2 data for miv-cel in generalized myasthenia gravis (gMG) at the AAN Annual Meeting. The updated data demonstrated that 100% of patients achieved sustained improvements across key clinical measures over 52 weeks, reinforcing confidence in the effectiveness of miv-cel's treatment. The well-tolerated profile further enhances its potential as a leading therapy in the field. Kyverna is currently progressing into a Phase 3 trial to further evaluate miv-cel's efficacy.
Read more →KYTX▲ +5.4%on this news
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
Kyverna Therapeutics announced promising results from its registrational trial of miv-cel for stiff person syndrome (SPS), presented at the AAN Annual Meeting. The single-dose therapy achieved strong, statistically significant improvements in mobility and allowed all participants to discontinue chronic immunotherapies. Miv-cel's performance across primary and secondary endpoints highlights its potential as the first approved treatment for SPS, which could transform care for patients suffering from this debilitating condition. The company is preparing to submit a Biologics License Application (BLA) for miv-cel's initial indication.
Read more →KYTX▲ +5.4%on this news
Highlighting New Data from Our Neuroimmunology Franchise at AAN
Kyverna Therapeutics presented new data regarding its neuroimmunology franchise at the AAN conference, focusing on the autoimmune CAR T therapy miv-cel for Stiff Person Syndrome (SPS) and generalized myasthenia gravis (gMG). The presentation highlighted promising results from ongoing clinical trials, indicating a high percentage of patients experiencing clinically meaningful benefits without the need for chronic immunotherapies. The company is currently preparing for a Biologics License Application (BLA) submission, driven by the positive data that underscores miv-cel's potential as a first-in-class therapy addressing significant unmet medical needs in the autoimmune space.
Read more →KYTXKyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
Kyverna Therapeutics will host a conference call on April 22, 2026, to discuss data from its KYSA-8 trial of miv-cel in stiff person syndrome and longer-term data from the KYSA-6 Phase 2 trial in generalized myasthenia gravis. These findings will be presented at the AAN Annual Meeting in Chicago. Miv-cel is a promising CAR T-cell therapy aimed at treating autoimmune diseases.
Read more →About Kyverna Therapeutics, Inc.
Headquarters5980 HORTON STREET, EMERYVILLE, CA
BIOPHARMAWATCH ELITE PLUS
Trade the next KYTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime